ICOTF - iCo Therapeutics shares jump after COVID-19 treatment testing deal

iCo Therapeutics ([[ICOTF]] +25.8%) announces that its wholly owned subsidiary, Amphotericin B Technologies, has entered into an agreement with IIT Research Institute to test the in vivo efficacy of the company's novel oral amphotericin B asset ("iCo-019") against SARS-CoV-2 in the hACE2 mouse model.The company expects that the iCo-019 Study will be completed by the end of Q2 2021."We have some exciting preliminary data suggesting the anti-viral activity of our compound against SARS-CoV-2 at concentrations that are not toxic to the cells themselves," Kishor Wasan, Chief Medical and Scientific Officer of Skymount Medical said.

For further details see:

iCo Therapeutics shares jump after COVID-19 treatment testing deal